Gilead Sciences gears up for 2008 with promising new drugs

01/23/2008 | Investor's Business Daily

Analysts believe that Gilead Sciences can expect another good year because of its robust pipeline of new drugs and its HIV treatments. FDA approval this year of two drug candidates -- inhaled antibiotic aztreonam lysine for the treatment of cystic fibrosis and HIV drug Viread for the treatment of chronic hepatitis B in adults -- are expected to boost the biopharmaceutical firm's profits.

View Full Article in:

Investor's Business Daily

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ